Congenital defects of carbohydrate metobolism

Slides:



Advertisements
Similar presentations
Protein-, Mineral- & Fluid-Modified Diets for Kidney Diseases
Advertisements

Cellular Disorders. Everything that our bodies do each and every day is because of cells and their various functions If all or some of these cells lose.
Sugar Catabolism and Biosynthesis Medical Biochemistry, Lecture 42.
CF Related Diabetes ADEU November Cystic Fibrosis Genetic disorder Exocrine pancreas dysfunction Autosomal recessive inheritance Several identified.
Galactosemia screening why? when? how? Clinical Children`s Hospital “Louis Turcanu ” Timisoara, Romania.
Cystic Fibrosis Fred Hill, MA, RRT. Overview Cystic fibrosis is the most common fatal, inherited disease in the U. S. Cystic fibrosis is the most common.
Cystic Fibrosis Gina Brandl, RN BSN Nursing Instructor, Pediatrics.
Chapter 11 Newborn Screening. Introduction Newborns can be screened for an increasing variety of conditions on the principle that early detection can.
Islets of Langerhan. Prof. K. Sivapalan Islets of Langerhan2 Histology. A cells 20 % [glucogon] B cells 50% [Insulin] D cells 8% [somatostatin]
SS© 2007 AT&T Knowledge Ventures. All rights reserved. AT&T and the AT&T logo are trademarks of AT&T Knowledge Ventures. A Brief Discussion on the Identification.
Tiffany Rimmer.  CF is the most common lethal autosomal recessive genetic disease in Caucasians.  It affects over 30,000 individuals in the United States.
CYSTIC FIBROSIS FANOURAKI MARIA CHARALAMPIDOU ALEXANDRA
Inherited Metabolic Disorders of Carbohydrate Metabolism
1 RETROSPECTIVE EVALUATION OF THE PATIENTS WITH CYSTIC FIBROSIS DR.LALE PULAT SEREN ZEYNEP KAMİL MATERNITY AND CHILDREN’S TRAINING AND RESEARCH HOSPITAL.
Metabolism of disaccharides: Fructose and Galactose Dr. Sooad Al-Daihan Biochemistry department.
CARBOHYDRATE METABOLISM- INHERITED DISORDERS DR. Tagreed Osman.
Symptoms In newborns: – Delayed growth – Failure to gain weight normally during childhood – No bowel movements in first 24 to 48 hours of life – Salty-tasting.
Patient: Lily Johnson Case study by Alexa Angelo
Metabolic diseases of the liver Central role in metabolism Causes and mechanisms of dysfunction Clinical patterns of metabolic disease Clinical approach.
Cystic Fibrosis Islamic university Nursing College.
Sweat Test. A sweat test measures the amount of salt chemicals (sodium and chloride) in sweat. Sodium and chloride are part of your body’s electrolyte.
Diabetic Ketoacidosis DKA)
Galactose γάλακτος galactose glucose In the human body, glucose is changed into galactose via hexoneogenesis to enable the mammary glands to secrete lactose.
Glycogen storage disease
WHAT IS GLYCOGEN STORAGE DISEASES (GSD) ?. - GSD has 2 classes of cause : (a) Genetic (b) Acquired.
BIOC/DENT/PHCY 230 LECTURE 7. Fed state characterised by: o increased plasma concentration of fuel molecules o increased rate of uptake of fuel molecules.
Endocrine Block Glucose Homeostasis Dr. Usman Ghani.
· It is the storage from of glucose in animals
Dietary Management In Glycogen Storage Disorders Metabolic Integration and Disorders (CHS 344)
Type 0 Type I Glycogen Storage Diseases Type IV Type VII Type III.
Cystic Fibrosis Board Review February 11, Cystic Fibrosis b Mutation in CFTR gene--epithelial chloride channels mutation causes decreased Cl transport.
Glucose Homeostasis By Dr. Sumbul Fatma.
Metabolism of pentoses, glycogen, fructose and galactose Alice Skoumalová.
Presenters: PICU/AO1 UNIT Moderators: Dr Somwe Dr Mwenechanya
Objectives Review the causes of cystic fibrosis (CF) Describe the symptoms and laboratory findings in CF Review current and emerging CF treatments Review.
Disorders and other genetic traits Bio II. Chromosomal Inheritance All but one pair of chromosomes in males and females are the same. –Autosomes - Nonsex.
HEREDITARY METABOLIC DISEASES. Particular risk factors are: Advanced maternal age (e.g. Down's syndrome) Family history of inherited diseases (e.g. fragile.
Glycogen storage diseases Dr. Samah Kotb 2015 Cellular Biochemistry and Metabolism2 (CLS 333)
Dr. Samah Kotb Nasr Eldeen Lecturer of Biochemistry Cellular Biochemistry and Metabolism (CLS 333 ) Inborn Errors of Metabolism (IEM)
GLYCOGEN METABOLISM Dr Vivek Joshi, MD.
Cystic Fibrosis.
Fructose and galactose metabolism Uronic acid pathway
Glycogen Storage Diseases:
Disorders of Malabsorption. Malabsorption It is a descriptive term of many diseases and is not a diagnosis It is a descriptive term of many diseases and.
Diet Therapy and Childhood Diseases (Part A) NS 335 Unit 8 Erin Hetrick, MS, RD, LDN.
Many hundred disorders resulting from this type of inheritance are known An affected individual is homozygous for the abnormal gene, having inherited an.
Dr. S.Chakravarty MD. Points to be covered-  Introduction  Biomedical importance  Glycogen Synthesis- Glycogenesis  Regulation of glycogenesis  Glycogen.
CARBOHYDRATE TOLERANCE Glucose tolerance is the ability to regulate the blood glucose concentration after the administration of a test dose of glucose.
In the name of GOD carnitine transporter deficiency
Diabetes mellitus.
Inherited metabolic disorders
Carbohydrate Storage & Disorders By Jennifer Turley and Joan Thompson © 2013 Cengage Module 3.4.
 Autosomal Recessive Inheritance  Disorders that are inherited in an AR manner manifest only when both copies of a gene pair located on an autosome.
Objectives: · Metabolism of fructose · Metabolism of galactose · Pathway of alcohol metabolism · Explain the metabolic defects (fructosuria , hereditary.
Cystic fibrosis. Etiology and epidemiology Cystic fibrosis (CF) is an autosomal recessive disorder that is the most common life limiting genetic disease.
Endocrine Block Glucose Homeostasis Dr. Usman Ghani.
Hemorrhagic disease of the newborn
Cystic Fibrosis Chris Kingsnorth.
Diabetes Mellitus Nursing Management.
Glycogen Storage Diseases:
Glucose Homeostasis By Dr. Sumbul Fatma.
Lecture 6 GLYCOGEN METABOLISM
By Dr. Dipendra Raj Pandeya, PhD Assistant Professor Department of Clinical Laboratory Science College of Applied Medical Sciences Al Jouf University.
Inborn Error of Metabolism
Disorders of carbohydrate metabolism
HEREDITARY METABOLIC DISEASES
CARBOHYDRATES METABOLISM & DISORDERS
Glycogen Storage Diseases
Inherited Metabolic Disorders
Cellular Disorders.
Presentation transcript:

Congenital defects of carbohydrate metobolism

CLASSICAL GALACTOSEMIA Defective enzyme: Galactose-1-phosphate uridyltransferase (incidence 1:40,000) Mechanism: Accumulation of galactose-1-phosphate causes intracellular ATP depletion and very toxic for liver, kidney and brain.

CLASSICAL GALACTOSEMIA Galactitol galaktokinase Galactose-1P Galactose-1-phosphate uridyltransferase epimerase Glucose

Clinical findings: Progressive symptoms after start of milk feeds Clinical findings: Progressive symptoms after start of milk feeds. Usually starting on the 3rd and 4th day. Vomiting, diarrhea, jaundice, disturbances of liver function tests, death from severe liver and renal failure, sepsis (especially by E. Coli), bilateral cataracts (due to galactitol accumulation)

Diagnosis Low galactose-1-phosphate uridyltransferase activity (Beutler test) High galactose and galactose-1-phosphate levels (N: 0-0.3 mg/dL) in serum or erythrocytes. Renal tubular damage: Generalized aminoaciduria, albuminuria, Reducing substances in urine (Fehling or Benedict test) due to glucosuria and galactosuria.

Therapy: Lactose-free and galactose restricted diet throughout life Therapy: Lactose-free and galactose restricted diet throughout life. Keep galactose-1-phosphate levels under 5mg/dL. Complications: Mild mental retardation, ataxia, tremor; gonodal dysfunction, disturbed pubertal development (especially in girls)

EPIMERASE DEFICIENCY Galactose Galactose-1P Glucose Galactitol galaktokinase Galactose-1P Galactose-1-phosphate uridyltransferase epimerase Glucose Most of the cases are asymptomatic. Symptomatic cases like classical galactosemia.

GALACTOKINASE DEFICIENCY Galactose Galactitol galaktokinase Galactose-1P Galactose-1-phosphate uridyltransferase epimerase Glucose

GALACTOKINASE DEFICIENCY Clinical findings Rapidly progressing bilateral central cataract. Reversible in the first few weeks of life. No hepatorenal damage Therapy: Lactose-free diet

HEREDITARY FRUCTOSE INTOLERANCE Fructokinase Fructose-1P Aldolase Glucose

HEREDITARY FRUCTOSE INTOLERANCE Defective enzyme: Aldolase B (incidence 1:20,000) Mechanism: Accumulation of fructose-1-phosphate causes intracellular ATP depletion and very toxic for liver, kidney and brain.

Clinical findings: Symptoms after weaning or supplementary feeds. Vomiting, apathy liver dysfunction with hepatomegaly, hypoglycemia (inhibition of glycogenolysis) renal tubular dysfunction, distribution of liver function tests, failure to thrive, aversion to fructose containing foods/sweets, no caries.

Diagnosis: Clinical symptoms with fructose loading (dangerous Diagnosis: Clinical symptoms with fructose loading (dangerous!); positive effect of withdrawing fructose; enzyme studies. Renal tubular damage: Generalized aminoaciduria, albuminuria, Reducing substances in urine (Fehling or Benedict test) due to glucosuria and galactosuria. Therapy: Strict fructose restricted diet throughout life.

ESSENTIAL FRUCTOSURIA Defective enzyme: Fructokinase Clinical findings: asymptomatic. Diagnosis: Positive reducing substance in urine (incidental finding)

Glycogen storage diseases

Glycogen storage diseases – Classification Liver involvement and hypoglycemia (Type 0, I, VI) Muscle involvement (Type II, V, VII) Liver involvement, muscle involvement and hypoglycemia (Type III). Liver cirrhosis: (Type III , Type IV).

GSD Type O Defect: Liver glycogen synthase Clinical: Convulsions in the early hours of morning No Hepatomegaly Hypoglycemia inresponsive to glucagon

Type I a (von Gierke)/ Clinic/Laboratory Neonatal hypoglycemia Lactic acidosis, ketosis Hepatomegaly Hyperuricemia  gout Hyperlipidemia Lipid accumulation in the cheeks (doll facies).

Type I a (von Gierke)/Diagnosis Hypoglycemia inresponsive to glucagon Glucose challange test: Glucose (increase), Lactate (decrease) Diagnosis: Low liver glucose-6-phosphatase levels.

GSD Type I a (von Gierke)/Therapy Avoid hypoglycemia by means of continous carbohydrate intake. Frequent meals (every 2-3 hours in infants, 4-6 hours in school age) Slowly resorbed carbohydrates (raw –uncooked- starch) Limited fructose, lactose, no sucrose, Nights: Continous intake of glucose polymers (starch) via nasogastric tube

GSD Type Ib Enzyme: Glucose-6-phosphate transporter (edoplasmic reticulum) Clinical: looks like GSD type Ia Plus: neutropenia, leucocyte dysfunction, frequent infections, Crohn like inflammatory bowel disease. Treatment of neutropenia: G-CSF and GM-CSF

GSD type Ic and Id Clinical: Similar GSD type Ia Ic: Inorganic phospate transport defect (T2 protein disorder) Id: GLUT 7 microsomal transport defect

GSD type VI Hers disease Enzyme: Liver phosphorylase defect Clinical: Failure to thrive, hepatomegaly, mild hypoglycemia Diagnosis: Elevated lactate and transaminases, enzyme studies: Liver, erythrocytes, leucocytes Prognosis: Fairly good, often asymptomatic

GSD type VII Tarui disease Enzyme: phosphofruktokinase (muscle, erythrocyte, platelets) Severe myopathy Postprandial exercize intolerance (does not respond to glucose infusion) Mild hemolytic anemia Hyperuricemia (post exercize) PAS positive, abnormal amilopectin accumulation

GSD type IX Enzyme: Phosphorylase kinase X related liver form (most frequent) AR liver and muscle form AR liver form Muscle form Cardiac form

GSD type II (Pompe disease) Enzyme: alpha-1,4-glucosidase (asid maltase); lysosomal enzyme; minimal role in glucose metabolism. Storage of cholesterol esters and triglycerides. İnfantile form : Severe cardiomyopathy and myopathy, hypotonia, hepatomegaly, failure to thrive, untreated fatal in the first year Juvenile-adult form: Slowly progressing skeletal muscle weakness, no cardiomyopathy Diagnosis; Vacuolated lymphocytes, EKG: PR-shortness and massive QRS waves, enzyme studies Enzyme replacement therapy

GSDType III (Cori / Forbes disease) Defective Enzyme: Debrancher enzyme= amylo-1, 6-glucosidase accumulation of limit dextrin in liver and muscle. Type IIIa: (Liver+muscle involvement): In infancy same as in GSD Type I; but normal lactate/uric acid, mild hypoglycemia, improvement in childhood, hepatomegaly, normal kidney size, failure to thrive; Progressive myopathy, cardiomyopathy, neuropathy Type IIIb: (Only liver involvement) Diagnosis: decreased alanine, leucine, isoleucine, elevated valine; increased transaminases and cholesterol. Enzyme studies: Liver, muscle, erythrocytes, fibroblasts Therapy: Frequent feeding, maintain normoglycemia

GSD Type IV (Andersen disease) Defective Enzyme: Branching enzyme = amylo-1,4-> 1,6 transglucosidase; accumulation of amylopectin like glycogen molecule Classic form: failure to thrive, hepatomegaly, progressive liver disease -> cirhossis, liver failure, often fatal by age of 4-5 years Mild form; Non-progressive Neuromuscular forms Enzyme studies: Liver, muscle, erythrocytes, fibroblasts Therapy: Liver Transplantation ?

GSD Type V (McArdle disease) Enzyme: Muscle phosphorylase Clinical: Adolescent/Adult onset; exercise intolerance, fatigue, muscle cramps, myoglobinuria No postischemic hyperlactatemia, elevated CK Diagnosis: muscle biopsy Therapy: Avoid exessive exercise, creatine supplementation

Glucose transport defects

GLUT 1 deficiency Clinical: Epileptic encephalopathy, microcephaly, psyhomotor retardation Diagnosis: Fasting CSF: CSF glucose/ Blood glucose<0.45; lactate: N, or decreased Therapy: Ketogenic diet. Avoid these drugs: barbiturates, ethanol, methylxantines Prognosis: Satisfactory with early treatment

GSD tip XI (Fanconi-Bickel syndrome) GLUT 2 defect Clinically resembles GSD type Ia Dwarfism, Fanconi syndrome, rickets Fasting hypoglycemia (no response to glucagon), postprandial hyperglycemia, aminoaciduria, phosphaturia, glucosuria Glycogen accumulation in liver and kidneys

Congenital glucose-galactose malabsorption SGLT1 deficiency Severe intestinal glucose and galactose transport defects, mild renal transport defect. Clinical: Severe neonatal diarrhoea, dehydration Diagnosis: Mild glucosuria, reducing substance in stools, normal fructose tolerance Therapy: Dietary replacement of gucose/galactose with fructose

Renal glucosuria SGLT2 deficiency Renal transport defect of glucose and galactose No intestinal defect Benign glucosuria with normal blood glucose and absence of generalized tubular dysfunction. Therapy: None

CYSTIC FIBROSIS

Kistik fibrozda solunum epitelinde görülen sıvı sekresyonu ve emilimindeki bozukluklar

Ter sekresyonu

Cystic fibrosis-Genetics Cystic fibrosis gene is localized in the long arm of 7th chromosome (7q31.2). Cystic fibrosis gene codes cystic fibrosis transmembrane regulator (CFTR). There are more than 600 mutations. The most frequent mutation is delta-F508, 70-80% in USA and 30% in Turkey) Incidence: 1:2500 in Caucasians, less frequent in Orientals where cholera is endemic. Incidence in Turkey is not known, but presumed to be high.

PATHOGENESIS CTFR is inserted in the cell membranes and has the properties of ion channels. In cystic fibrosis cAMP-dependent chloride channels that regulate the water secretion and sodium channels regulate the water reabsorption are defective.

Apical membranes of epithelial cells of exocrine glands are impermeable to chloride, and secondarily sodium and water. Additionally epithelial cells reabsorb excessive amount amounts of sodium and secondarily water. Decreased water secretion and increased water reabsorption (dehydrated secretions) lead obstruction, cysts and fibrosis in the exocrine glands (bronchial tree, pancreatic duct, gastrointestinal glands etc) with the exception of sweat gland.

In sweat glands, chloride secretion and thereby the water secretion is normal in the secretory coil. On the other hand sodium and secondarily chloride reabsorption by the ductus is decreased. Therefore excessive amounts of salt are lost in the sweat (chloride levels are more than 60 mEq/L).

Kistik fibroz: Patogenez

CLINICAL MANIFESTATIONS The most life threatening clinical features of CF, are pulmonary obstruction and infections. Thick mucous secretions are associated with chronic obstructive lung disease predominantly involving the small airways. Recurrent and persistent infections with Pseudomonas aeroginosa and cepecia (virtually diagnostic) and Staphylococcous lead to bronchiectasis and respiratory failure, often accompanied by cor pulmonale and death

CLINICAL MANIFESTATIONS In 80-90% of the patients exocrine pancreatic deficiency causes steatorhea and failure to thrive. In 10-20% of the patients, meconium ileus occurs in the neonatal period. Failure to pass meconium in the first 24-48 hours of life. Abdominal roentgenograms show dilated loops of bowel with a collection of granular ground-glass material in the lower central abdomen.

Meconium ileus

CLINICAL MANIFESTATIONS Excessive lost of salt in the sweat leads hyponatremic dehydration in young children especially during high environmental temperature. Secondary hyperaldosteronism causes hypopotasemia and metabolic alkalosis (Pseudo-Bartter syndrome). 10% of patients diabetes mellitus develops, especially after the age of ten.

CRITERIA FOR DIAGNOSIS OF CYSTIC FIBROSIS Typical pulmonary manifestations and/or Typical gastrointestinal manifestations and/or A history of cystic fibrosis in the family plus * Sweat chloride concentration >60mEq/L and/or * Pathologic CTFR mutation on both chromosomes.

NEONATAL SCREENING Most of the patients with CF can be identified by determination of immunoreactive tripsinogen in blood spots (Guthrie card). This test is neither sufficiently sensitive nor spesific for CF. This test is not valid after the age of three months (Serum tripsinogen levels decrease during progressive pancreatic damage).

Pulmonary therapy The objective of pulmonary therapy is to clear secretions from airways and to control infections Chest percussion + postural drainage Bronchodilators: ß-sympathomimetic agents, teophylline Expectorants: Are not effective, curcumin may be helpful (stimulation of Cl channel) %3-7 NaCl inhalation

Antibiotic therapy Aerosol and/or intravenous: (Pseudomonas is more difficult to treat and rarely is eradicated) Pseudomonas aeroginosa: amikasin, gentamycin, tobramycin, netilmycin, imipenem Staphylococcous aereus: voncomycin, oxacillin

Nutritional therapy High caloric diet (150% of normal calorie) without fat restriction Pancreatic enzyme replacement Fat-soluble vitamins (A,D,E,K) supplementation